Patent Term Extended Under 35 U.S.C.   156

   An interim extension of the term of U.S. Patent No. Re. 34,617 has
been granted under 35 U.S.C.    156(e)(2) for a period of nine (9)
months from the extended expiration date of the patent, February 12,
1997. The patent received two one-year extensions under 35 U.S.C.
156(d)(5). See 1159 OG 77, February 22, 1994, and 1171 OG 32, February
14, 1995. Subsequently, the product "Olean" (olestra) was granted
permission for commercial marketing or use by the Food and Drug
Administration and an application for patent term extension under 35
U.S.C.    156 was timely filed by The Procter and Gamble Company. The
patent then received a one-year extension under 35 U.S.C.    156(e)(2).
See 1184 OG 39, March 12, 1996. Initial PTO review of the application to
date indicates that the patent would be eligible for a maximum extension
of the patent term for a period of two years from the effective date of
receipt of permission for commercial marketing or use for the product
Olean (January 30, 1996) under 35 U.S.C.      156(g)(6)(C) and